Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer
This study is currently recruiting participants.
Verified May 2013 by Brown University
Sponsor:
Maria Constantinou
Information provided by (Responsible Party):
Maria Constantinou, Brown University
ClinicalTrials.gov Identifier:
NCT01650350
First received: July 24, 2012
Last updated: May 9, 2013
Last verified: May 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
will scientifically evaluate whether Low Dose Naltrexone (LDN) has activity in refractory solid tumors within the context of a phase II clinical study
| Condition | Intervention | Phase |
|---|---|---|
|
Melanoma Castrate Resistant Prostate Cancer Renal Cancer |
Drug: Naltrexone |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer: A Phase II Brown University Oncology Group Research Project |
Resource links provided by NLM:
Further study details as provided by Brown University:
Primary Outcome Measures:
- determine the response rate of low dose naltrexone for patients with advanced melanoma, castrate refractory prostate cancer (CRPC) or renal cancer [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To assess the toxicity associated with low dose naltrexone for melanoma, CRPC and renal cancer. [ Time Frame: 3 months ] [ Designated as safety issue: Yes ]
| Estimated Enrollment: | 13 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | June 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Low Dose Naltrexone
LDN, 5 mg/day-(1 cycle = 28 days).
|
Drug: Naltrexone |
Detailed Description:
Three types of solid tumors will be studied in this protocol: Melanoma, castrate resistant prostate cancer and kidney cancer. Systemic chemotherapy may weaken the immune system reducing the potential for response to LDN. Therefore, patients must either have not had previous chemotherapy or patients must not have received more than 1 prior chemotherapy regimen which must have been completed at least 6 months prior to LDN. Systemic chemotherapy has at best modest activity in melanoma, CRPC and renal cancer.
- Melanoma will be evaluated since the responding patient at the Miriam Hospital had melanoma. Immunomodulatory agents such as ipilimumab have already demonstrated a survival advantage in melanoma.
- Castrate Resistant Prostate Cancer (CRPC): It is common in CRPC for patients to have rising PSA after failure of androgen deprivation. These patients may be asymptomatic or minimally symptomatic and there is reluctance to initiate treatment with systemic chemotherapy with standard docetaxel since this agent has substantial toxicity and will impair quality of life. Waiting until symptomatic disease progression in patients with CRPC and rising PSA is a commonly utilized strategy. These patients are excellent candidates for a treatment with minimal toxicity such as LDA. The immunomodulatory agent Sipuleucel also improves survival in prostate cancer suggesting that an agent such as LDN could also be helpful.
- Renal cancer will also be studied since this is a disease that has activity with immunomodulants such as IL-2 and interferon. Targeted therapies are generally used for renal cancer. Chemotherapy has minimal activity so most patients are chemotherapy-naive.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Conditions for Patient Eligibility
Each patient must meet all of the following inclusion criteria to be enrolled in the study:
- Histologically or pathologically confirmed melanoma, renal cancer or prostate cancer.
- Patients with melanoma or renal cancer must have metastatic disease.
- Patients with melanoma or renal cancer must have radiographically measurable advanced disease. Patients with measurable cutaneous lesions are also evaluable patients with prostate cancer must be castrate refractory and must have radiographically assessable metastatic disease or must have rising PSA on two sequential measurements.
- No prior chemotherapy, or have not received cytotoxic chemotherapy within the 6 months prior to entry..
- No radiation for 3 weeks prior to beginning Naltrexone
- No requirement for opioid analgesics orNo use of opioid analgesics for at least 10 days.
- Absolute neutrophil count ≥ 1,000/uL, platelet ≥ 75,000/uL.
- Total bilirubin ≤ 1.5x upper institutional limit (ULN) and AST or ALT ≤ 3x ULN;
- No prior history of hepatic failure, cirrhosis or hepatic encephalopathy
- ECOG performance status 0 to 2.
- Creatinine < 1.5 x ULN
- Life expectancy of at least 8 weeks.
- Age ≥ 18 years
- Women of childbearing potential must have a negative pregnancy test.
- Men and women of childbearing potential must be willing to consent to using effective contraception while on treatment and for at least 1 months thereafter.
- Voluntary written informed consent.
- Conditions for Patient Ineligibility Patients meeting any of the following exclusion criteria are not to be enrolled in the study.
- Must not have uncontrolled severe, intercurrent illness.
- Women who are breast-feeding.
- Patients who have undergone major surgery or radiotherapy within the last 3 weeks.
- Patients on concurrent anticancer therapy.
- Patients with known, untreated brain metastasis
- Co-medication that may interfere with study results; e.g opioids
- Known hypersensitivity to any component of naltrexone
- Current or prior alcohol dependence
- Patients who could benefit from conventional therapy are not eligible.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01650350
Contacts
| Contact: Kayla Rosati | 401-863-3000 | kayla_rosati@brown.edu |
Locations
| United States, Rhode Island | |
| Miriam Hospital | Recruiting |
| Providence, Rhode Island, United States, 06902 | |
| Contact: Maureen Jean 401-793-4283 mjean@lifespan.org | |
| Principal Investigator: Maria Constaninou, MD | |
| Sub-Investigator: anothy mega, md | |
| Sub-Investigator: howard safran, md | |
Sponsors and Collaborators
Maria Constantinou
Investigators
| Study Director: | Howard Safran, MD | Brown University Oncology Research Group |
More Information
No publications provided
| Responsible Party: | Maria Constantinou, Principal Investigator, Brown University |
| ClinicalTrials.gov Identifier: | NCT01650350 History of Changes |
| Other Study ID Numbers: | BrUOG 275 |
| Study First Received: | July 24, 2012 |
| Last Updated: | May 9, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Brown University:
|
Melanoma Prostate Cancer Renal Cancer |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Kidney Neoplasms Melanoma Prostatic Neoplasms Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Neuroendocrine Tumors |
Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Nevi and Melanomas Genital Neoplasms, Male Genital Diseases, Male Prostatic Diseases Naltrexone Narcotic Antagonists Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 21, 2013